Saccharomyces boulardii administration changes gut microbiota and reduces hepatic steatosis, low-grade inflammation, and fat mass in obese and type 2 diabetic db/db mice.
Saccharomyces boulardii administration changes gut microbiota and reduces hepatic steatosis, low-grade inflammation, and fat mass in obese and type 2 diabetic db/db mice.
复制标题
DOI：
10.1128/mbio.01011-14
复制
发表时间：
2014-06-10
期刊：
影响因子：
6.4
通讯作者：
Cani PD
中科院分区：
文献类型：
--
作者：
Everard A;Matamoros S;Geurts L;Delzenne NM;Cani PD
越来越多的证据表明，肠道微生物是调节能量稳态、代谢性炎症、脂质代谢和葡萄糖代谢的关键因素。因此，由选择性发酵寡糖或益生菌引起的肠道微生物群调节构成了肥胖生理病理中的一个有趣的靶点。然而，到目前为止，还没有益生菌酵母在这方面进行过研究。因此，我们的研究旨在评估研究最多的益生菌酵母（即博氏酵母菌）对肥胖小鼠肥胖和相关代谢特征的影响，如脂肪团发育、肝脂肪变性和低度炎症。对瘦素抵抗型肥胖和2型糖尿病小鼠（db/db）每天灌胃博氏梭菌，持续4周。我们发现博拉氏梭菌处理的小鼠表现出体重、脂肪量、肝脏脂肪变性和炎症性。有趣的是，博氏弓形虫对宿主代谢的这些影响与肠道的局部影响有关。博氏弧菌增加了盲肠重量和盲肠组织重量，但也引起了门、科和属水平肠道微生物组成的剧烈变化。这些肠道菌群对博氏弧菌的反应也可能与宿主代谢反应有关。总之，本研究首次证明了博氏弧菌可能作为一种有益的益生菌治疗肥胖和2型糖尿病。到目前为止，还没有研究益生菌酵母在肥胖和2型糖尿病中的作用。在这里，我们发现用博氏酵母治疗的2型糖尿病和肥胖小鼠（db/db）表现出体重、脂肪量、肝脏脂肪变性和炎症基调的降低。这些对宿主代谢的影响与肠道的局部影响有关。重要的是，通过焦磷酸测序，我们发现博氏沙门氏菌处理诱导了门、科和属水平肠道微生物群组成的变化。此外，我们发现肠道菌群对博氏弧菌的反应与几种宿主代谢反应相关。
Growing evidence shows that gut microbes are key factors involved in the regulation of energy homeostasis, metabolic inflammation, lipid metabolism, and glucose metabolism. Therefore, gut microbiota modulations caused by selectively fermented oligosaccharides or probiotic bacteria constitute an interesting target in the physiopathology of obesity. However, to date, no probiotic yeast has been investigated in this context. Therefore, our study aimed to evaluate the impact of the most-studied probiotic yeast (i.e., Saccharomyces boulardii Biocodex) on obesity and associated metabolic features, such as fat mass development, hepatic steatosis, and low-grade inflammation, in obese mice. S. boulardii was administered daily by oral gavage to leptin-resistant obese and type 2 diabetic mice (db/db) for 4 weeks. We found that S. boulardii-treated mice exhibited reduced body weight, fat mass, hepatic steatosis, and inflammatory tone. Interestingly, these effects of S. boulardii on host metabolism were associated with local effects in the intestine. S. boulardii increased cecum weight and cecum tissue weight but also induced dramatic changes in the gut microbial composition at the phylum, family, and genus levels. These gut microbiota changes in response to S. boulardii may also be correlated with the host metabolism response. In conclusion, this study demonstrates for the first time that S. boulardii may act as a beneficial probiotic treatment in the context of obesity and type 2 diabetes. To date, no probiotic yeast have been investigated in the context of obesity and type 2 diabetes. Here we found that type 2 diabetic and obese mice (db/db) treated with Saccharomyces boulardii exhibited reduced body weight, fat mass, hepatic steatosis, and inflammatory tone. These effects on host metabolism were associated with local effects in the intestine. Importantly, by using pyrosequencing, we found that S. boulardii treatment induces changes of the gut microbiota composition at the phylum, family, and genus levels. Moreover, we found that gut microbiota changes in response to S. boulardii were correlated with several host metabolism responses.